Avascular Necrosis of the Femoral Head
18
5
9
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
6%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (18)
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis
Z1 Hip System: Post-Market Clinical Follow Up Study
The Medacta Quadra-P Anteverted Study
The Medacta International SMS Post-Marketing Surveillance Study
Actis Total Hip System 2 Year Follow-up
Avenir Complete Post-Market Clinical Follow-Up Study
The Medacta International AMIStem-P Post-Marketing Surveillance Study
Desflurane Potentially Induces Postoperative Cognitive Dysfunction in Elderly Patients Undergoing Perioperative Procedures by Modulating Cdc42 and Clock Proteins
Safety and Performance Assessment of the SYMBOL Range of Medical Devices in Patients Underlying Total Hip Arthroplasty
Bone Marrow Cells With Core Decompression for AVN Treatment
Corin MiniHip and Trinity Cup Clinical Surveillance Study
Biologically Assisted Core Decompression of the Femoral Head Using the PerFuse Instrument and BioCUE
Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip
Outcome After Avascular Necrosis of the Femoral Head in Young Patients
Tritanium® Study in Japan
Ceramic-on-Ceramic Versus Ceramic-on-HXLPE THA
Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Avascular Necrosis of the Femoral Head